HC Wainwright Reaffirms Buy Rating for Indaptus Therapeutics (NASDAQ:INDP)

HC Wainwright reaffirmed their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP) in a research note published on Monday, Benzinga reports. The firm currently has a $12.00 price objective on the stock.

Indaptus Therapeutics Price Performance

INDP opened at $2.65 on Monday. Indaptus Therapeutics has a fifty-two week low of $1.56 and a fifty-two week high of $4.08. The firm has a market capitalization of $22.63 million, a price-to-earnings ratio of -1.44 and a beta of 1.28. The company’s 50 day moving average price is $2.09 and its two-hundred day moving average price is $2.10.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. As a group, equities research analysts predict that Indaptus Therapeutics will post -1.73 EPS for the current year.

Institutional Investors Weigh In On Indaptus Therapeutics

A number of institutional investors have recently modified their holdings of the company. Citadel Advisors LLC bought a new position in Indaptus Therapeutics during the fourth quarter worth $29,000. Northern Trust Corp bought a new position in Indaptus Therapeutics during the first quarter worth $41,000. Renaissance Technologies LLC bought a new position in Indaptus Therapeutics during the second quarter worth $51,000. State Street Corp bought a new position in Indaptus Therapeutics during the first quarter worth $78,000. Finally, Vanguard Group Inc. boosted its stake in Indaptus Therapeutics by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after acquiring an additional 5,517 shares in the last quarter. 7.06% of the stock is owned by institutional investors.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial.